Joint Meeting - Nonprescription Drugs Advisory Committee & Pulmonary - Allergy Drugs Advisory Committee

May 11, 2001

Petition 98P-0610/CP1 - submitted by Blue Cross of California requesting
fexofenadine hydrochloride, loratadine and cetirizine hydrocholoride be switched to OTC status

Open Public Hearing

Eric J Schenkel, MD, Valley Allergy and Asthma Treatment Center   pdf   htm

Steven Weinstein, MD, University of California at Irvine   pdf  htm

Importance of Accurate Diagnosis of Allergy Prior to Use of Second-Generation Antihistamines, Ivor Emanuel, MD, University of California, representing Pharmacia Diagnostics   pdf   htm

Daniel A Hussar, PhD, University of the Sciences in Philadelphia   pdf   htm

Charles Cutler, MD, American Association of Health Plans   pdf

Frank Brocato, Employers Health Coalition  pdf   htm

Mark Cloutier, MPH, MPP, RXHealthValue    pdf   htm

Michael Parker, MD, American Academy of Otolaryngic Allergy (AAOA)   pdf

Bobby Lanier, MD, American Academy of Asthma, Allergy and Immunology (AAAAI) and College of Allergy, Asthma and Immunology  pdf  htm

Presentation Opposing the Switch of Fexofenadine Hydrochloride, Loratadine and Cetrizine Hydrochloride to OTC Status Due to Safety Issues, J A Quel, MD, Hispanic American Allergy, Asthma, Immunology Association (HAAMA)   pdf   htm

Michael Kaliner, MD, World Allergy Association   pdf   htm

Nancy Sander, Allergy and Asthma Network Mothers of Asthmatics   pdf   htm

Statement by Steven Sesterhenn, MD, MBA   pdf

Phil Walson, MD, University of Cincinnati, representing Whitehall Robins   pdf   htm

Bryan R Luce PhD, MBA, MEDTAP International   pdf   htm

Joel W Hay PhD, Value in Health   pdf   htm

Steve Francesco, Francesco International   ppt   htm

Steve Francesco, newsletter SWITCH   pdf   htm

Bertram A Spilker, PhD, MD, Pharmaceutical Research and Manufacturers of American (PhRMA)   pdf   htm

R William Soller PhD, Consumer Healthcare Products Association   pdf